Healthcare / Pharmaceutical RetailersHKSE
$0.52
+0.02 (+5.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-42.5M · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$57M
P/E
86.7x
↑EV/EBITDA
5.5x
↓ROE
0.1%
↓Gross Margin
16.5%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-2.8%
FCF CAGR
—
FCF margin
-9.3%
FCF / Net income
-246.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.09B · net income $413000.0 · FCF $-101.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.09B | $1.09B | $1.30B | $1.27B | $1.19B |
| Net Income | $413000.00 | $413000.00 | $-105.4M | $-187.6M | $-675.4M |
| EBITDA | $12.6M | $12.6M | $-94.6M | $-160.8M | $-560.8M |
| EPS | 0.01 | 0.01 | -1.81 | -4.27 | — |
| Gross Margin | 16.5% | 16.5% | 16.5% | 16.0% | 13.2% |
| Operating Margin | -2.6% | -2.6% | -6.6% | -13.3% | -37.4% |
| Net Margin | 0.0% | 0.0% | -8.1% | -14.7% | -57.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.13 | 0.10 | 0.01 |
| Current Ratio | 1.46 | 1.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-101.8M | $-101.8M | $-18.2M | $-42.5M | $-109.6M |
| Returns | |||||
| ROE | 0.1% | 0.1% | -33.5% | -46.0% | -117.5% |
| Valuation | |||||
| P/E | 86.67 | 86.67 | — | — | — |
| EV/EBITDA | 5.48 | 5.48 | — | — | — |
| P/B | 0.10 | 0.10 | 0.22 | 0.16 | 0.12 |
| Growth & Yield | |||||
| Revenue Growth | -16.0% | -16.0% | 1.8% | 7.5% | — |
| EPS Growth | 100.3% | 100.3% | 57.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
97.4%
EPS terminal req.
$0.05
Spread vs growth
2.9%
5Y implied EPS CAGR
56.2%
EPS terminal req.
$0.06
Spread vs growth
44.1%
10Y implied EPS CAGR
31.1%
EPS terminal req.
$0.09
Spread vs growth
69.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-58.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.81 → 0.01
Residual
-58.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.